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ABSTRACT 
Objective: The present work aims to develop and evaluate sublingual tablets of Zolpidem Tartrate used for the short-term treatment of insomnia. 
Methods: The tablet of Zolpidem Tartrate was prepared by direct compression technique using two classes of super disintegrates represented by 
Crospovidone and Sodium Starch Glycolate (SSG) and the efficiency of these super disintegrants in the tablets was compared with various tests like 
disintegration time, waiting time, water absorption ratio, in-vitro dissolution profile and stability study. 
Results: The disintegration efficiency of Crospovidone is better than SSG. Fourier Transform Infrared (FT-IR) spectrum of pure drug and the 
mixture of drug polymers revealed no chemical interaction. The pre-compression study indicated good flow properties of the bulk powder. In-vitro 
drug release from the formulations was studied using buffer pH 6.8. From the entire formulations, F5 and F6 containing 4 % and 5 % of 
Crospovidone conceded as an optimized formulation which is showing the drug release of 102.00±0.21 % and 103.10±0.42 % in 30 min 
considerably.  
Conclusion: The results indicated that delivery of Zolpidem Tartrate into the systemic circulation via the sublingual route to improving its bio-
availability and circumvent the first-pass effect. The optimized formulations were also found to be stable during stability studies conducted for 3 mg 
as per ICH guidelines. 
Keywords: Insomnia, Zolpidem Tartrate, Crospovidone, Sodium Starch Glycolate, In-vitro disintegration, In-vitro drug release, Sublingual tablet 
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
In the current scenario, there is an increased incidence of sleep 
disorder due to several reasons. Sleep disorders (somnipathies) are 
conditions characterized by disruptions of sleep quality or of sleep 
pattern. They can involve difficulty falling asleep (prolonged sleep 
onset latency); difficulty staying asleep (disturbance of sleep 
maintenance), sleep of poor quality (unrefreshing), or combinations of 
these and can lead to poor health and quality of life problems [1]. In 
medical practice, insomnia is one of the most common disorders and, 
for its treatment a lot of pharmacological agents are available. In this 
regard, some benzodiazepines are the drugs of choice because they 
possess negligible side effects and toxicity. However, the long-term 
treatment of insomnia with benzodiazepines is problematic since it 
results in the development of tolerance and dependence. Further 
improvement in the management of insomnia and other sleep 
disorders resulted after the recent introduction of non-benzodiazepine 
hypnotics such as zolpidem, zopiclone, and zaleplon. In particular 
Zolpidem, the active moiety of Zolpidem Tartrate is chemically, N, N, 6-
trimethyl-2-p-tolylimidazo [1,2-a] pyridine-3-acetamide L-(+)-tartrate 
(2:1) that exhibit strong hypnotic and sedative actions with negligible 
anxiolytic, muscle relaxant, or anticonvulsant properties and is widely 
prescribed for the short-term treatment of insomnia [2]. Zolpidem 
Tartrate [1, 3-5] is a white to off-white crystalline powder and is 
slightly soluble in water, sparingly soluble in alcohol, propylene glycol, 
practically insoluble in methylene chloride, freely soluble in 0.1N 
sulfuric acid and inorganic solvents like acetonitrile, methanol. 
Zolpidem Tartrate acts by GABA-A Receptor Agonists and causes 
Sedative and Hypnotic action. For adults, the recommended initial 
dose is 5 mg for women and either 5 or 10 mg for men. 
Sublingual route is one of the oral mucosal drug delivery systems, 
where the placement of the drug under the tongue and drug reaches 
directly into the blood stream through a ventral surface of the 
tongue and the floor of the mouth. The drug solutes are rapidly 
absorbed into the reticulated vein which lies underneath the oral 
mucosa, and transported through the facial veins, internal jugular 
vein, and brachiocephalic vein and then drained into systemic 
circulation [6]. The sublingual route usually produces a faster onset 
of action than orally ingested tablets and the portion absorbed 
through the sublingual blood vessels bypasses the hepatic first-pass 
metabolic processes [7-9].  
Presently EDLUAR (5 and 10 mg) and INTERMEZZO (1.75 and 3.5 mg) 
are the Zolpidem Tartrate products marketed for the treatment of 
insomnia as a sublingual tablet, and no generics are available in the 
market. In this study, we tried to develop Zolpidem Tartrate sublingual 
tablets as an alternate formulation of the available products. 
MATERIALS AND METHODS 
Materials 
Zolpidem Tartrate gift sample from Medreich, Bengaluru, India, 
Crospovidone, Microcrystalline Cellulose, Poloxamer 188 and 
Aspartame was purchased from Sigma-Aldrich Corporation, 
Bengaluru, India. SSG, Disodium hydrogen phosphate, Magnesium 
stearate and Sodium hydroxide pellets were purchased from S. D. 
Fine Chemical Limited, Mumbai, India. Potassium dihydrogen 
phosphate and potassium bromide (IR grade) were purchased from 
Merck, Mumbai, India. Mannitol was purchased from Roquette 
Pharma, Bengaluru, India. 
FT-IR spectroscopic study 
This was carried out to find out the compatibility between the drug 
Zolpidem Tartrate and the polymers such as Crospovidone, SSG, 
Microcrystalline cellulose, Poloxamer, Aspartame. The prepared pellet 
was kept onto the sample holder and scanned from 4000 cm-1 to 400 
cm-1
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 in Perkin Elmer FT-IR spectrophotometer. The spectra obtained 
were compared and interpreted for the functional group peaks. 
Separately sift the Zolpidem Tartrate, Crospovidone XL, Mannitol 
(Pearlitol DC400), SSG, Microcrystalline cellulose, Poloxamer, 
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Aspartame through #30 mesh and Magnesium stearate through #60 
mesh and collected individually in a double-lined polyethylene bag. 
Then, mix the Zolpidem Tartrate, Mannitol (Pearlitol DC400), 
Crospovidone XL, SSG, Microcrystalline cellulose in different 
concentration as given in (table 1 and 2) by using mortar and pestle 
for 10 min. To the premixed blend, Aspartame and Poloxamer 188 
was added and thoroughly mixed for 15 min. As a lubricant add 
Magnesium stearate to the above blend. Then tablets were prepared 
by direct compression by 12 station tablet compression machine 
manufactured by Rimek, India (I. P/B. P/U. S. P. Standard) of 6 mm 
Flat Faced Bevel Edged (FFBE) punches. The total weight of the 
tablet was made up to 100 mg.
 
Table 1: Composition for the preparation of zolpidem tartrate sublingual tablets 
Name of the ingredients Quantity/Unit dose (mg) 
F001 F002 F003 F004 F005 F006 
Zolpidem Tartrate 5.00 5.00 5.00 5.00 5.00 5.00 
Mannitol (Pearlitol DC 400) 60.00 60.00 57.00 - 56.00 55.00 
Mannitol (Parteck M-200) - - - 57.00 - - 
Croospovidone XL 1.00 2.00 3.00 3.00 4.00 5.00 
Sodium Starch Glycolate - - - - - - 
Microcrystalline Cellulose 28.00 28.00 30.00 30.00 30.00 30.00 
Poloxamer 188 1.00 1.00 1.00 1.00 1.00 1.00 
Aspartame 2.00 2.00 2.00 2.00 2.00 2.00 
Magnesium Stearate  3.00 3.00 2.00 2.00 2.00 2.00 
Average weight of tablets (mg) 100.00 100.00 100.00 100.00 100.00 100.00 
 
Table 2: Composition for the preparation of zolpidem tartrate sublingual tablets 
Name of the ingredients Quantity/Unit dose (mg) 
F007 F008 F009 F010 F011 F012 
Zolpidem Tartrate 5.00 5.00 5.00 5.00 5.00 5.00 
Mannitol (Pearlitol DC 400) 60.00 60.00 - - - 60.00 
Mannitol (Parteck M-200) - - 57.00 60.00 65.00 - 
Croospovidone XL - - - - - - 
Sodium Starch Glycolate 1.00 2.00 3.00 4.00 5.00 5.00 
Microcrystalline Cellulose 29.00 28.00 30.00 26.00 20.00 25.00 
Poloxamer 188 1.00 1.00 1.00 1.00 1.00 1.00 
Aspartame 2.00 2.00 2.00 2.00 2.00 2.00 
Magnesium Stearate  3.00 2.00 2.00 2.00 2.00 2.00 
Average weight of tablets (mg) 100.00 100.00 100.00 100.00 100.00 100.00 
 
Evaluation of zolpidem tartrate compressed tablets [10, 11] 
Pre-compression parameters 
Pre-compression parameters Bulk Density (Db), Tapped Density 
(Dt), Compressibility index (Carr’s Index) (CCI), Hausner’s Ratio and 
Angle of Repose were carried out. 
Post-compression parameters [12-14] 
Thickness of prepared tablets 
The thickness and diameter of the tablet were measured using 
Vernier calipers. It is measured in mm. 
Friability (F) 
The friability was determined by using Roche friabilator. The 






 = initial weight of the tablets 
final
Weight variation test 
 = Final weight of tables 
20 tablets were selected at random from a lot, weighed individually, 
and the average weight was determined. The percent deviation of each 
tablet weight against the average weight was calculated. The test 
requirements are met; if not more than two of the individual weight 
deviates from the average weight of not more than existing 5 %. 
Uniformity of drug content 
The prepared tablets were tested for their drug content. 20 tablets 
of each formulation were finely powdered; weight equivalent to 100 
mg of powder was accurately weighed, and the drug Zolpidem 
tartrate was completely extracted with methanol and the solution 
was filtered. 1 ml of the filtrate was suitably diluted using phosphate 
buffer of pH 6.8 and analyzed for Zolpidem tartrate content by a UV 
spectrophotometer at 241 nm. 
Wetting time [13] 
The tablets wetting time was measured by a procedure modified 
from that reported by Bi et al. The tablet was placed at the center of 
two layers of absorbent paper fitted into a dish. After the paper was 
thoroughly wetted with distilled water, excess water was completely 
drained out of the dish. The time required for the water to diffuse 
from the wetted absorbent paper throughout the entire tablets was 
then recorded using a stopwatch. 
Water absorption ratio [13] 
A piece of tissue paper folded twice was placed in a small Petri dish 
Containing 6 ml of water. A tablet was put on the tissue paper and 
allowed to completely wet. The wetted tablet was then weighted. Water 
absorption ratio (R), was determined using the following equation. 
R = 100 × Wa–Wb
Where, 
/Wa 
Wa = Weight of tablet after water absorption. 
Wb
In-vitro disintegration time [15] 
 = Weight of tablet before water absorption. 
In-vitro disintegration study of Zolpidem Tartrate was carried out 
by using Disintegration Tester (USP) ED2L model. One tablet was 
placed in each tube of the basket. The basket with the bottom 
surface made of a stainless steel screen (mesh no. 10) was immersed 
in a water bath at 37±2 °C. The time required for the complete 
disintegration of the tablet in each tube was determined. 
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In-vitro dissolution study [15] 
The in-vitro dissolution studies of prepared Zolpidem Tartrate were 
carried out for the formulations using phosphate buffer of pH 6.8 for 
30 min in USP apparatus type II. The samples were measured by UV 
Spectrophotometer at 241 nm for Zolpidem Tartrate against a blank. 
The release studies were conducted in triplicate and the mean 
values were plotted versus time. Calibration cure for Zolpidem 




Stability study [16] 
The selected formulations were packed in the strip packaging Alu-
Alu, which was placed in the cardboard box and labeled. They were 
then stored at 40 °C/75 % RH and kept for three months and 
evaluated for their Hardness, drug content, and drug release at 
specific intervals of time as per ICH Guidelines. 
The in-vitro release data obtained were statistically analyzed by one-
way ANOVA followed by Tykey method. A probability value of 
p<0.05 was considered as statistically significant. 
RESULTS AND DISCUSSION 
Pre-formulation studies 
Organoleptic properties of zolpidem tartrate were found to be 
normal. 
FT-IR spectroscopic study 
The IR spectrum of the pure drug and the pure drug with used 
excipients is given in table 3 and fig. 1, 2, 3, 4, 5, 6, 7, 8 and 9. It 
concludes that Zolpidem Tartrate is compatible with all the 
excipients used in the formulation.
 
Table 3: Compatibility studies of zolpidem tartrate 
Excipients Drug/Excipients ratio Physical description initial 40 °C/75 % RH 
1st 2 week nd 3 week rd week 
Drug 1:1 White amorphous powder * * * 
Drug+Mannitol 1:1 White amorphous powder * * * 
Drug+Crospovidone 1:1 White amorphous powder * * * 
Drug+SSG 1:1 White amorphous powder * * * 
Drug+Poloxamer 1:1 White amorphous powder * * * 
Drug+MCC 1:1 White amorphous powder * * * 
Drug+Aspartame 1:1 White amorphous powder * * * 
Drug+Magnesium stearate 1:1 White amorphous powder * * * 
 
 
Fig. 1: FTIR spectra of zolpidem tartrate 
 
 
Fig. 2: FTIR spectra of zolpidem tartrate with pearlitol DC 400 
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Fig. 3: FTIR spectra of zolpidem tartrate with parteck M 200 
 
 
Fig. 4: FTIR spectra of zolpidem tartrate with crospovidone 
 
 
Fig. 5: FTIR spectra of zolpidem tartrate with SSG 
 
 
Fig. 6: FTIR spectra of zolpidem tartrate with MCC 
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Fig. 7: FTIR spectra of zolpidem tartrate with poloxamer 
 
 
Fig. 8: FTIR spectra of zolpidem tartrate with aspartame 
 
 
Fig. 9: FTIR spectra of zolpidem tartrate with magnesium stearate 
 
Table 4: Evaluation of pre-compression parameters of formulations F1-F6 
Formulations Bulk density (g/cc)  Tapped density (g/cc) Compressibility index (%) Hausner’s ratio Angle of repose (θ) 
F1 0.420±0.03 0.500±0.04 16.00±0.02 1.19±0.01 27.02±0.13 
F2 0.431±0.05 0.512±0.06 15.82±0.04 1.18±0.01 25.00±0.11 
F3 0.378±0.06 0.445±0.06 15.05±0.03 1.17±0.03 24.25±0.14 
F4 0.430±0.08 0.506±0.03 15.01±0.02 1.17±0.05 24.00±0.12 
F5 0.391±0.02 0.439±0.04 10.93±0.05 1.12±0.02 20.12±0.13 
F6 0.399±0.03 0.456±0.01 11.50±0.04 1.14±0.03 22.13±0.11 
*mean±SD, n = 3. 
 
Evaluation of pre-compression parameters 
Pre-compression parameters of all formulations were in acceptable 
range as per the specification [17, 18]. And the results like, Bulk 
density ranges from 0.358±0.06 gm/cc to 0.431±0.05 gm/cc, Tapped 
density ranges from 0.410±0.01 gm/cc to 0.512±0.06 gm/cc, 
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Compressibility or Carr’s index ranges from 10.93±0.05 % to 16±0.02 
%, Hausner’s ratio ranges from 1.09±0.06 to 1.19±0.01 and angle of 
repose ranges from 20.12±0.13 ° to 27.02±0.13 °. Hence, it concludes 
that all the prepared formulations fall under excellent flow property 
except F1 and F12 which falls under good flow property, and it is given 
in the table no 12 and 13 for the F1-F6 and F7-F12 respectively.
 
Table 5: Evaluation of pre-compression parameters of formulations F7-F12 
Formulations Bulk density (g/cc)  Tapped density (g/cc) Compressibility index (%) Hausner’s ratio Angle of repose (θ) 
F7 0.395±0.04 0.450±0.02  12.22±0.05  1.13±0.03  22.52±0.12 
F8 0.358±0.06 0.410±0.01  12.68±0.04  1.14±0.06  22.60±0.15 
F9 0.410±0.03 0.466±0.06  12.01±0.02  1.13±0.03  22.97±0.12 
F10 0.405±0.07 0.459±0.02  11.76±0.04  1.13±0.05  25.37±0.15 
F11 0.398±0.05 0.450±0.04  11.55±0.02  1.13±0.03  23.12±0.11 
F12 0.384±0.08  0.432±0.04  11.11±0.05  1.09±0.06  26.78±0.16 
*mean±SD, n = 3. 
 
Evaluation of post-compression parameters 
The results for Thickness (2.5-3.5 mm), Hardness (3.2-3.4 kg/cm2
 
), 
Friability (Not more than 1 %), Average weight (Range is 90-110 
mg), Weight variation (±5 % from the average weight) and content 
uniformity (90-110 %). All these parameters of formulation F1-F4 
are given in table 6, F5-F8 is given in table 7 and F9-F12 is given in 
table 8. This shows all formulations are within the prescribed ranges 
as specified by the pharmacopeia [19]. Hence, all prepared 
formulations pass the post-compression studies. 
Table 6: Post-compression parameters of formulations F1–F4 
Tests Specification F1 F2 F3 F4 
Thickness* (mm) 2.5-3.5 mm 2.9±0.01  2.7±0.01  2.9±0.02  3.0±0.01 
Hardness* (kg/cm2 3.2-3.4 kg/cm ) (%) 3.4±0.10  3.3±0.05  3.3±0.02  3.2±0.01 
Friability* Not more than (1 %) 0.10  0.09  0.12  0.11 
Average weight* (mg) Range is 90-110 mg 100±0.5 105±0.8  98±0.2  110±0.5 
Weight variation* ±5 % from the average weight 2.5 %  2.1 %  2.6 %  2.10 % 
Assay* Zolpidem Tartrate 90-110 % 94.20±0.52  98.60±0.64  99.30±0.46  97.78±0.50 
*mean±SD, n = 3. 
 
Table 7: Post-compression parameters of formulations F5–F8 
Tests Specification F5 F6 F7 F8 
Thickness* (mm) 2.5-3.5 mm 2.5±0.01  2.6±0.01  3.2±0.02  2.9±0.01 
Hardness* (kg/cm2 3.2-3.4 kg/cm ) (%) 3.3±0.10  3.2±0.05  3.4±0.02  3.3±0.01 
Friability* Not more than (1 %) 0.18  0.10  0.05  0.08 
Average weight* (mg) Range is 90-110 mg 99±0.5  105±0.8  98±0.2  110±0.5 
Weight variation* ±5 % from the average weight 2.6%  2.7%  2.5%  2.1% 
Assay* Zolpidem Tartrate 90-110 % 102.80±0.25  104.09±0.5  93.37±0.71  96.08±0.62 
*mean±SD (n=3) 
 
Table 8: Post-compression parameters of formulations F9–F12 
Tests Specification F9 F10 F11 F12 
Thickness* (mm) 2.5-3.5 mm 2.8±0.02  2.5±0.01  3.3±0.02  2.6±0.01 
Hardness* (kg/cm2 3.2-3.4 kg/cm ) (%) 3.4±0.10  3.2±0.05  3.3±0.12  3.4±0.11 
Friability* Not more than (1 %) 0.15  0.14  0.12  0.10 
Average weight* (mg) Range is 90-110 mg 95±0.5  90±0.5  90±0.2  98±0.5 
Weight variation* ±5 % from the average weight 2.2 %  2.1 %  2.6 %  2.7 % 
Assay* Zolpidem Tartrate 90-110 % 92.00±0.72  98.72±0.52 97.23±0.53  99.00±0.56  
*mean±SD, n = 3. 
 
Table 9: Evaluations for wetting time, water absorption ratio and disintegration time of Formulations F1-F6 
Formulations Wetting time (s)  Water absorption ratio (%) AM±SD  Disintegration time (s) 
F1 25.00±2.00  32.03±0.75  29±1.15 
F2 22.67±1.53  34.69±1.33  25±1.12 
F3 18.00±1.00  40.11±1.17  20±1.23 
F4 16.33±0.58  39.94±1.12  18±1.23 
F5 8.22±0.58  48.00±1.46  14±1.16 
F6 11.12±0.58  45.50±1.08  16±1.41 
*mean±SD, n = 3. 
 
Evaluations from wetting time, water absorption ratio and 
disintegration time 
The evaluation of prepared all formulations for wetting time ranges 
from 8.22±0.58 s to 28.00±1.00 s, water absorption ratio ranges 
from 32.03±0.75 % to 48.00±1.46 % and disintegration time ranges 
from 14±1.16 s to 31±1.15 s and the results of the formulations from 
F1-F6 are given table 9 and the formulations F7-F12 are given in 
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table 10. The values of wetting time, water absorption ratio and 
disintegration time were in the acceptable range as per the 
pharmacopeia [19]. Results of all formulations are variable and 
depend on the type and quantity of mannitol and super 
disintegrating agents used. Formulation F1-F6 contains 
Crospovidone while the formulations F7-F12 contain SSG as a super 
disintegrating agent. Also, it was observed that as the concentration 
of both super disintegrating agent increases, wetting time and 
disintegration time decreases and water absorption ratio increases 
but contradictorily effect seen in F6 formulation as compared to F5. 
Hence, from the table 9 and 10, it was concluded that formulation F5 
was the best among all.
 
Table 10: Evaluations for wetting time, water absorption ratio and disintegration time of Formulations F7-F12 
Formulations Wetting time (s)  Water absorption ratio (%) AM±SD  Disintegration time (s) 
F7 28.00±1.00  35.03±0.85  31±1.15 
F8 26.67±2.53  36.69±1.33  30±1.12 
F9 24.00±1.00  37.11±1.16  28±1.23 
F10 19.33±0.58  39.94±1.13  24±1.23 
F11 17.22±0.58  41.00±1.46  20±1.16 
F12 13.12±0.58  44.50±1.11  17±1.41 
*mean±SD, n = 3. 
 
Iv-vitro dissolution study 
In-vitro dissolution studies to the prepared Zolpidem Tartrate 
sublingual tablets are given in table 11 of F1-F6 and in table 12 of 
F7-F12 formulations. The graphical representations of formulation 
F1-F3, F4-F6, F7-F9 and F10-F12 are given in fig. 10, 11, 12 and 13 
respectively; this concludes that at 30th
Among all prepared formulation, F5 showed immediate and highest 
drug release due to the type and concentration of both mannitol and 
super disintegrating agents used.
 min the in-vitro release of all 
formulations ranges from 48.45±0.26 % to 103.10±0.42.  
  
Table 11: Iv-vitro release studies of formulations F1 to F6 
Time (min) % Drug release 
F1  F2 F3  F4 F5 F6 
0 0.00  0.00  0.00  0.00  0.00  0.00  
2 7.63±0.09  41.63±0.31  41.26±0.49  44.92±0.33  94.29±0.21  84.05±0.52 
4 11.68±0.57  67.46±0.26  68.56±0.25  71.14±0.66  95.18±0.45  95.18±0.45  
6 16.50±0.44  75.88±0.57  75.52±0.36  75.92±0.21  99.73±0.52  95.99±0.60 
8 22.81±0.02  78.49±0.16  77.03±0.62  77.43±0.54  100.76±0.22  97.60±0.26 
10 26.23±0.64  81.48±0.45  77.82±0.11  78.22±0.50  100.78±0.41  99.23±0.35 
15 34.42±0.49  83.76±0.66  78.97±0.35  79.75±0.45  101.00±0.50  100.96±0.46 
20 42.65±1.14  86.04±0.59  81.60±0.42  81.64±0.40  101.80±0.31  101.10±0.32 
25 47.27±0.56  87.60±0.21  83.14±0.13  83.55±0.35  102.00±0.12  102.00±0.37 
30 51.92±0.34  91.36±0.35  83.95±0.19  87.65±0.02  102.00±0.21  103.10±0.42 
*mean±SD, n = 3. 
 
Table 12: Iv-vitro release studies of formulations F7 to F12 
Time (min) % Drug release 
F7  F8 F9  F10 F11 F12 
0 0.00  0.00  0.00  0.00  0.00  0.00   
2 3.96±0.35  22.61±0.51  62.11±0.29  7.62±0.43  71.25±0.50 73.81±0.30  
4 7.64±0.52  38.83±0.39  72.69±0.30  27.41±0.25  72.01±0.36  82.63±0.28  
6 11.34±0.42  42.70±0.42  77.12±0.36  53.53±0.61  74.61±0.54  89.67±0.16 
8 18.71±0.50  48.42±0.36  78.64±0.33  62.23±0.35  80.14±0.31  92.73±0.25 
10 22.47±0.61  48.69±0.15  80.17±0.42  62.94±0.23  82.04±0.52  94.33±0.60 
15 33.57±0.10 54.80±0.41  83.16±0.24  79.01±0.56 82.48±0.21  95.21±0.25 
20 37.41±0.11  56.93±0.36  85.08±0.50  85.66±0.33  83.66±0.11  97.19±0.31 
25 41.27±0.35  65.29±0.38  85.54±0.61  90.52±0.38  84.11±0.40  100.00±0.26 
30 48.45±0.36  66.37±0.44  86.73±0.19  99.79±0.50  84.93±0.41  101.00±0.43 
*mean±SD, n = 3. 
 
 
Fig. 10: In-vitro release of formulations F1 to F3 
 
Fig. 11: In-vitro release of formulations F4 to F6 
Talluri et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 179-187 
186 
 
Fig. 12: In-vitro release of formulations F7 to F9 
 
Stability study 
The accelerated stability study of selected formulation F5 and 
formulation F6 results were given in table 13 and table 14 
respectively, and it concludes that all the parameters were within 
the acceptable ranges, and even there is no alteration in the physical 
appearance of formulation F5 and F6. 
 
 
Fig. 13: In-vitro release of formulations F10 to F12 
 
Table 13: Stability studies of sublingual tablets of zolpidem tartrate at 40 °C/75% RH of formulation (F5) 
Test Formulation at 40 °C/75 % RH 
Initial 1 Mo 2 Mo 3 Mo  
Hardness* 3.3 kg/cm 3.3 kg/cm2 2 3.2 kg/cm  3.2 kg/cm2 2 
Assay 102.80%  101.15%  100.72% 100.07% 
In-vitro disintegration time  14.00 s  14.32 s  15.00 s  15.12 s 
Time (min) % Drug release 
2 94.29±0.21 93.32±0.49  90.16±0.66 88.19±0.16 
4 95.18±0.45  94.19±0.71  92.17±0.82  90.57±0.28 
6 99.73±0.52  96.54±0.15  94.33±0.54  92.43±0.93 
8 100.76±0.22  99.66±0.84  97.81±0.16  93.06±0.85 
10 100.78±0.41  100.32±0.89  98.58±0.91  93.34±0.64 
15 101.00±0.50  100.75±0.61  99.24±0.93  94.95±0.28 
20 101.80±0.31  101.61±0.64  100.36±0.45  96.46±0.48 
25 102.00±0.12  101.65±0.14  100.00±0.37  98.67±0.63 
30 102.00±0.21  101.85±0.20  100.13±0.52 98.89±0.36 
 
Table 14: Stability studies of sublingual tablets of zolpidem tartrate at 40 °C/75 % RH of Formulation (F6) 
Test Formulation at 40 °C/75 % RH 
Initial 1 Mo 2 Mo 3 Mo  
Hardness* 3.2 kg/cm 3.1 kg/cm2 2 3.1 kg/cm  2 3.0 kg/cm  2 
Assay 104.09% 103.15%  102.72%  102.07% 
In-vitro disintegration time  16.00 s  16.32 s  18.00 s  18.12 s 
Time (min) % Drug release 
2 84.29±0.52 82.62±0.45  80.16±0.65  77.19±0.20 
4 90.37±0.25  84.29±0.27  83.77±0.65  80.13±0.19 
6 95.99±0.60  87.68±0.13  85.54±0.25  83.37±0.89 
8 97.60±0.26  94.20±0.64  92.23±0.68  88.23±0.95 
10 99.23±0.35  96.72±0.36  94.65±0.85  90.45±0.74 
15 100.96±0.46  97.80±0.45  98.59±0.36  94.95±0.28 
20 101.10±0.32  99.56±0.58  99.24±0.93  94.42±0.90 
25 102.00±0.37  100.19±0.14  99.00±0.54  95.76±0.14 
30 103.10±0.42  100.95±0.30  99.16±0.45  97.56±0.50 
 
CONCLUSION 
Sublingual tablets of Zolpidem Tartrate can be efficiently and 
successfully formulated by the direct compression method. Under 
the pre-formulation studies, API (Active Pharmaceutical Ingredient) 
characterization and drug-excipient compatibility studies were 
carried out. The API characterization showed compliance with the 
drug characteristics. The formulations were prepared by using 
Crospovidone and SSG as the super disintegrant along with the other 
excipients. The rapid disintegration was observed for Crospovidone 
containing tablets, comparing the two classes of super disintegrants 
represented by Crospovidone and SSG. The disintegration efficiency 
was found to be better for Crospovidone compared to SSG. 
From all the formulations, F5 and F6 containing 4% and 5% 
Crospovidone showed less wetting time and disintegration time also 
the dissolution study that has been carried out was found to be 
faster when compared with that of other formulations. Various 
physicochemical parameters tested for these formulations have 
shown good results. Therefore, F5 and F6 were selected as the 
optimized formulations. 
It was concluded that this lowered dose of sublingual tablets of 
Zolpidem Tartrate (5 mg) prepared by direct compression technique 
has enough efficacy and can be used efficiently as an alternative to 
other marketed formulations of Zolpidem Tartrate for short-term 
treatment of insomnia. 
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